CT-95
Advanced solid tumors expressing Mesothelin (MSLN)
Phase 1Active (First-in-Human study announced Nov 2025)
Key Facts
Indication
Advanced solid tumors expressing Mesothelin (MSLN)
Phase
Phase 1
Status
Active (First-in-Human study announced Nov 2025)
Company
About Context Therapeutics
Context Therapeutics is committed to advancing the treatment of solid tumors through the development of novel T cell engaging bispecific antibody therapies. The company's pipeline features three clinical-stage candidates targeting antigens such as Claudin 6, mesothelin, and Nectin-4, with a Phase 1 study for CT-95 initiated in late 2025. With a seasoned leadership team and a focus on innovative immunotherapeutic solutions, Context aims to improve outcomes in oncology by overcoming limitations of current TCE approaches.
View full company profile